Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: An observational retrospective report in real life clinical practice

Hematology Reports

Volumn 7, Issue 1, 2015, Pages 1-4

  Carpenedo, Monica ^a   Cantoni, Silvia ^b   Coccini, Veronica ^a   Fedele, Marilena ^a   Morra, Enrica ^b   Pogliani, Enrico Maria ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Immune thrombocytopenia; Sustained response; Thrombopoietin receptor agonists

Indexed keywords

AZATHIOPRINE; CHEMOKINE RECEPTOR AGONIST; CYCLOSPORIN; RITUXIMAB; ROMIPLOSTIM; STEROID; THROMBOPOIETIN RECEPTOR; VINCRISTINE; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG REEXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PHLEBITIS; RELAPSE; REMISSION; RETREATMENT; RETROSPECTIVE STUDY; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT DURATION; VERY ELDERLY; YOUNG ADULT;

EID: 84923384685     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2015.5673     Document Type: Article

References (18)

1. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Ann Rev Med 2009;60:193-206.
2. Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Hematol 2013;161:411-23.
3. Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, openlabel EXTEND study. Blood 2013;121:537-45.
4. Bussel JB, Rodeghiero F, Lyons R, et al. Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: report of 9 cases. Blood 2011;118:3281.
5. Newland A, Cervinek L, Eggermann J, et al. Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim – four European case studies. Haematologica 2011;96:ABS237.
6. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013;53:2807-12.
7. Thachil J, Salter I, George JN. Complete remission of refractory immune thrombocytopenia (ITP) with a short course of Romiplostim. Eur J Hematol 2013;91:376-7.
8. Bussel JB, Wang X, Eisen M. Case studies of remission in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim. Blood 2013;122:ABS328.
9. Bussel JB, Saleh MN, Wong RSM, et al. Update on the safety and efficacy of EXTENDed treatment with eltrombopag (EPAG) in adults with chronic immune thrombocytopenia (ITP). Blood 2013;122:ABS2315.
10. González-López TJ, González-Porras JR, Arefi M, et al. Sustained response after short-medium-term treatment with eltrombopag in patients with ITP. Blood 2013;122:ABS2323.
11. Mahévas, M, Fain, O, Ebbo, M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Hematol 2014;165:865-9.
12. Stasi R, Newland A, Godeau B, et al. An interim analysis of a phase 2, single-arm study of platelet responses and remission rates in patients with immune thrombocytopenia (ITP) receiving romiplostim. Blood 2013;122:ABS1074.
13. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93.
14. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010;116:4639-45.
15. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147-50.
16. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+ Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Hematol 2007; 79:310-6.
17. Bussel JB, Psaila B, Saleh MN, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood 2008;112: ABS3431.
18. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011;CD008235.